An 81-year-old man was admitted to our hospital because of infiltrative shadow of his chest X-ray, which did not improve with the administration of antibiotics. Past medical history included nonvalvular atrial fibrillation (Af). He had been started with dabigatran etexilate for nonvalvular Af one month before admission, and just after administration cough and phlegm emerged. Bronchoalveolar lavage revealed elevated eosinophil of 40%. We diagnosed him as dabigatran etexilate-induced eosinophilic pneumonia. His respiratory condition and infiltative shadow on chest X-ray improved only with cessation of the drug, without the use of steroids. Dabigatran etexilate is a new drug that in March 2011 was approved in Japan. Although reports on dabigatran etexilate-induced eosinophilic pneumonia cannot be found yet, the possibility of drug-induced lung injury by dagigatran etexilate must be kept in mind.